[1] Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology, 2018; 67, 328−57. doi:  10.1002/hep.29367
[2] Younossi Z, Tacke F, Arrese M, et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology, 2019; 69, 2672−82. doi:  10.1002/hep.30251
[3] Powell EE, Wong VWS, Rinella M. Non-alcoholic fatty liver disease. Lancet, 2021; 397, 2212−24. doi:  10.1016/S0140-6736(20)32511-3
[4] Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol, 2020; 73, 202−9. doi:  10.1016/j.jhep.2020.03.039
[5] McGlinchey AJ, Govaere O, Geng DW, et al. Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease. JHEP Rep, 2022; 4, 100477. doi:  10.1016/j.jhepr.2022.100477
[6] Marušić M, Paić M, Knobloch M, et al. NAFLD, insulin resistance, and diabetes mellitus type 2. Can J Gastroenterol Hepatol, 2021; 2021, 6613827. doi:  10.1155/2021/6613827
[7] Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care, 2004; 27, 1487−95. doi:  10.2337/diacare.27.6.1487
[8] Yetim A, Şahin M, Kandemir İ, et al. Evaluation of the ability of insulin resistance and lipid-related indices to predict the presence of NAFLD in obese adolescents. Lipids Health Dis, 2024; 23, 208. doi:  10.1186/s12944-024-02144-7
[9] Shi JJ, Chen JH, Zhang ZQ, et al. Multi-dimensional comparison of abdominal obesity indices and insulin resistance indicators for assessing NAFLD. BMC Public Health, 2024; 24, 2161. doi:  10.1186/s12889-024-19657-6
[10] Hu MM, Yang JY, Gao BB, et al. Prediction of MASLD using different screening indexes in Chinese type 2 diabetes mellitus. Diabetol Metab Syndr, 2025; 17, 10. doi:  10.1186/s13098-024-01571-x
[11] Guo W, Lu J, Qin P, et al. The triglyceride-glucose index is associated with the severity of hepatic steatosis and the presence of liver fibrosis in non-alcoholic fatty liver disease: a cross-sectional study in Chinese adults. Lipids Health Dis, 2020; 19, 218. doi:  10.1186/s12944-020-01393-6
[12] Li XZ, Zhan FF, Peng T, et al. Association between the triglyceride-glucose index and non-alcoholic fatty liver disease in patients with atrial fibrillation. Eur J Med Res, 2023; 28, 355. doi:  10.1186/s40001-023-01188-2
[13] Han T, Li Y, Xiao J, et al. Diagnostic utility of triglyceride-glucose index in non-alcoholic fatty liver disease: a cross-sectional study on lean population. Diabetes Metab Syndr Obes, 2024; 17, 3547−56. doi:  10.2147/DMSO.S469398
[14] Zou HX, Xie JJ, Ma XP, et al. The value of TyG-related indices in evaluating MASLD and significant liver fibrosis in MASLD. Can J Gastroenterol Hepatol, 2025; 2025, 5871321. doi:  10.1155/cjgh/5871321
[15] Chen QL, Hu PP, Hou XX, et al. Association between triglyceride-glucose related indices and mortality among individuals with non-alcoholic fatty liver disease or metabolic dysfunction-associated steatotic liver disease. Cardiovasc Diabetol, 2024; 23, 232. doi:  10.1186/s12933-024-02343-7
[16] Wang YX, Fu C, Jin HW, et al. Lipid metabolism indicators provide tools for the diagnosis of non-alcoholic fatty liver disease: results of a nationwide survey. Front Endocrinol (Lausanne), 2025; 15, 1468228. doi:  10.3389/fendo.2024.1468228
[17] Huang QL, Tan XY, Wu QM, et al. Lipid accumulation product is a valid predictor of hepatic steatosis and nonalcoholic fatty liver disease. Biomark Med, 2024; 18, 123−35. doi:  10.2217/bmm-2023-0725
[18] Ma XM, Jia JG, Cui HZ, et al. Association between the triglyceride to high density lipoprotein cholesterol ratio and the incidence of metabolic dysfunction-associated fatty liver disease: a retrospective cohort study. BMC Gastroenterol, 2024; 24, 389. doi:  10.1186/s12876-024-03471-w
[19] Fan NG, Peng L, Xia ZH, et al. Triglycerides to high-density lipoprotein cholesterol ratio as a surrogate for nonalcoholic fatty liver disease: a cross-sectional study. Lipids Health Dis, 2019; 18, 39. doi:  10.1186/s12944-019-0986-7
[20] Chen ZK, Qin HL, Qiu SB, et al. Correlation of triglyceride to high-density lipoprotein cholesterol ratio with nonalcoholic fatty liver disease among the non-obese Chinese population with normal blood lipid levels: a retrospective cohort research. Lipids Health Dis, 2019; 18, 162. doi:  10.1186/s12944-019-1104-6
[21] Liu L, Shao YH, Feng EQ, et al. Risk of developing non-alcoholic fatty liver disease over time in a cohort of the elderly in Qingdao, China. Biomed Environ Sci, 2023; 36, 760−7.
[22] Kühn T, Nonnenmacher T, Sookthai D, et al. Anthropometric and blood parameters for the prediction of NAFLD among overweight and obese adults. BMC Gastroenterol, 2018; 18, 113. doi:  10.1186/s12876-018-0840-9
[23] Fracanzani AL, Petta S, Lombardi R, et al. Liver and cardiovascular damage in patients with lean nonalcoholic fatty liver disease, and association with visceral obesity. Clin Gastroenterol Hepatol, 2017; 15, 1604-11. E1.
[24] Pang Q, Zhang JY, Song SD, et al. Central obesity and nonalcoholic fatty liver disease risk after adjusting for body mass index. World J Gastroenterol, 2015; 21, 1650−62. doi:  10.3748/wjg.v21.i5.1650
[25] Li YM, Xiao X, Wang J, et al. Genetic variations and nonalcoholic fatty liver disease: field synopsis, systematic meta-analysis, and epidemiological evidence. Biomed Environ Sci, 2024; 37, 762−73.
[26] Abenavoli L, Milic N, Di Renzo L, et al. Metabolic aspects of adult patients with nonalcoholic fatty liver disease. World J Gastroenterol, 2016; 22, 7006−16. doi:  10.3748/wjg.v22.i31.7006
[27] Navarroza AMC, Wong SN. Comparison of clinical and metabolic profiles of lean versus non-lean nonalcoholic fatty liver disease. Indian J Gastroenterol, 2021; 40, 380−8. doi:  10.1007/s12664-021-01184-6
[28] Kim J, Shin SJ, Kim YS, et al. Positive association between the ratio of triglycerides to high-density lipoprotein cholesterol and diabetes incidence in Korean adults. Cardiovasc Diabetol, 2021; 20, 183. doi:  10.1186/s12933-021-01377-5
[29] Mitsuyoshi H, Yasui K, Hara T, et al. Hepatic nucleotide binding oligomerization domain-like receptors pyrin domain-containing 3 inflammasomes are associated with the histologic severity of non-alcoholic fatty liver disease. Hepatol Res, 2017; 47, 1459−68. doi:  10.1111/hepr.12883
[30] Chen LW, Huang MS, Shyu YC, et al. Gamma-glutamyl transpeptidase elevation is associated with metabolic syndrome, hepatic steatosis, and fibrosis in patients with nonalcoholic fatty liver disease: a community-based cross-sectional study. Kaohsiung J Med Sci, 2021; 37, 819−27. doi:  10.1002/kjm2.12395
[31] Pajuelo-Vasquez R, Benites-Meza JK, Durango-Chavez HV, et al. Diagnostic performance of the GGT/HDL-C ratio for NAFLD in adults with obesity undergoing bariatric surgery. Diabetes Res Clin Pract, 2024; 211, 111649. doi:  10.1016/j.diabres.2024.111649
[32] Zhu XP, Sun F, Gao X, et al. Predictive value of triglyceride glucose index in non-obese non-alcoholic fatty liver disease. BMJ Open, 2025; 15, e083686. doi:  10.1136/bmjopen-2023-083686
[33] Sheng GT, Lu S, Xie QY, et al. The usefulness of obesity and lipid-related indices to predict the presence of Non-alcoholic fatty liver disease. Lipids Health Dis, 2021; 20, 134. doi:  10.1186/s12944-021-01561-2
[34] Qian XY, Wu WW, Chen BY, et al. Value of triglyceride glucose-body mass index in predicting nonalcoholic fatty liver disease in individuals with type 2 diabetes mellitus. Front Endocrinol (Lausanne), 2025; 15, 1425024. doi:  10.3389/fendo.2024.1425024
[35] Li SY, Feng L, Ding J, et al. Triglyceride glucose-waist circumference: the optimum index to screen nonalcoholic fatty liver disease in non-obese adults. BMC Gastroenterol, 2023; 23, 376. doi:  10.1186/s12876-023-03007-8
[36] Zhang SJ, Du TY, Li MN, et al. Triglyceride glucose-body mass index is effective in identifying nonalcoholic fatty liver disease in nonobese subjects. Medicine (Baltimore), 2017; 96, e7041. doi:  10.1097/MD.0000000000007041
[37] Wang MY, Chang MX, Shen PP, et al. Application value of triglyceride-glucose index and triglyceride-glucose body mass index in evaluating the degree of hepatic steatosis in non-alcoholic fatty liver disease. Lipids Health Dis, 2023; 22, 186. doi:  10.1186/s12944-023-01954-5
[38] Wang XJ, Wang ZQ, Du W, et al. Predictive value of TyG and TyG-BMI indices for non-alcoholic fatty liver disease in high-altitude regions of China: a cross-sectional study. J Clin Med, 2024; 13, 7423. doi:  10.3390/jcm13237423
[39] Wu LM, He H, Chen G, et al. Associations between obesity and metabolic health with nonalcoholic fatty liver disease in elderly Chinese. Hepatobiliary Pancreat Dis Int, 2020; 19, 252−7. doi:  10.1016/j.hbpd.2020.02.010
[40] Dewidar B, Kahl S, Pafili K, et al. Metabolic liver disease in diabetes - from mechanisms to clinical trials. Metabolism, 2020; 111, 154299. doi:  10.1016/j.metabol.2020.154299
[41] Anık İlhan G, Yıldızhan B. Visceral adiposity indicators as predictors of metabolic syndrome in postmenopausal women. Turk J Obstet Gynecol, 2019; 16, 164−8. doi:  10.4274/tjod.galenos.2019.62558
[42] Li W, Wang Y, He F, et al. Association between triglyceride-glucose index and nonalcoholic fatty liver disease in type 2 diabetes mellitus. BMC Endocr Disord, 2022; 22, 261. doi:  10.1186/s12902-022-01172-7
[43] Tutunchi H, Naeini F, Mobasseri M, et al. Triglyceride glucose (TyG) index and the progression of liver fibrosis: a cross-sectional study. Clin Nutr ESPEN, 2021; 44, 483−7. doi:  10.1016/j.clnesp.2021.04.025
[44] Nie GQ, Hou SK, Zhang M, et al. High TG/HDL ratio suggests a higher risk of metabolic syndrome among an elderly Chinese population: a cross-sectional study. BMJ Open, 2021; 11, e041519. doi:  10.1136/bmjopen-2020-041519
[45] Yuan J, He XQ, Lu Y, et al. Triglycerides/high-density lipoprotein-cholesterol ratio outperforms traditional lipid indicators in predicting metabolic dysfunction-associated steatotic liver disease among U. S. adults. Front Endocrinol (Lausanne), 2025; 16, 1591241. doi:  10.3389/fendo.2025.1591241
[46] Zhang ZH, Tan L. Association of insulin resistance-related indicators with cardiovascular disease in Chinese people with different glycemic states. Front Endocrinol (Lausanne), 2025; 16, 1515559. doi:  10.3389/fendo.2025.1515559